2026-04-13T18:07:48Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/112092024-06-06T08:38:54Zcom_2072_378070com_2072_378040col_2072_378092

Cetuximab every 2 weeks versus standard weekly dosing administration schedule Bokemeyer, Carsten Dubreuil , Olivier GUIGAY, Joel Kasper, Stefan Pfeiffer, Per Ciardiello, Fortunato Tabernero, Josep Institut Català de la Salut [Bokemeyer C] The II Medical Clinic, Department of Oncology, Hematology & BMT with section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany. [Ciardiello F] Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Dubreuil O] Medical Oncology Unit, Diaconesses-Croix St Simon Hospital, Paris, France. [Guigay J] Groupe d’Oncologie Radiothérapie Tête Et Cou (GORTEC), Tours, France. [Kasper S] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. [Pfeiffer P] Department of Oncology, Odense University Hospital, Odense, Denmark. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Càncer - Tractament Anticossos monoclonals - Ús terapèutic CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal Other subheadings::Other subheadings::/therapeutic use DISEASES::Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales Otros calificadores::Otros calificadores::/uso terapéutico ENFERMEDADES::neoplasias Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia Dosing schedule; Efficacy; Pharmacokinetics Programa de dosificació; Eficàcia; Farmacocinètica Programa de dosificación; Eficacia; Farmacocinética Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Phase II trials have found comparable efficacy and safety for the weekly (Q1W) and Q2W schedules, and real-world studies have shown noninferiority of the Q2W compared with the Q1W schedule. Several guidelines recommend cetuximab Q2W administration as an alternative to the Q1W dosing schedule. Cetuximab Q2W can be administered with a Q2W dose of chemotherapy, making it a more convenient option to the Q1W schedule, potentially resulting in reduced costs for administration, increased flexibility for clinical staff and improved patient adherence. 2024-03-20T07:00:45Z 2024-03-20T07:00:45Z 2024-03 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Bokemeyer C, Ciardiello F, Dubreuil O, Guigay J, Kasper S, Pfeiffer P, et al. Cetuximab every 2 weeks versus standard weekly dosing administration schedule. Futur Oncol. 2024 Mar;20(7):393–407. 1744-8301 https://hdl.handle.net/11351/11209 10.2217/fon-2023-0282 37850363 001087969000001 http://hdl.handle.net/11351/11209 eng Future Oncology;20(7) https://doi.org/10.2217/fon-2023-0282 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf Future Medicine Scientia